Compare Citius Pharmaceuticals Inc (CTXR) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Entegris Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Entegris Inc trades at $161.02 (market cap $22.95B). The key difference: Entegris Inc is far larger — about 1146.9× Citius Pharmaceuticals Inc's market cap, and Entegris Inc pays a 0.27% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ENTG | |
|---|---|---|
Market Cap | $20.01M | $22.95B |
Sector | Health | Technology |
52-Week High | $1.82 | $184.00 |
52-Week Low | $0.48 | $68.80 |
Enterprise Value | $16.23M | $26.16B |
Dividend Yield | — | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
ENTG trades at $159.66, up 10.71% in 24 hours, reflecting strong momentum driven by Q2 2026 earnings beats and AI-driven semiconductor demand. The stock is near its 52-week high with bullish technical indicators and a consensus price target of $188.67. Revenue growth and margin expansion highlight operational strength, though elevated P/E and P/S ratios signal high valuation expectations.
Outlook is positive with continued earnings growth potential from semiconductor industry tailwinds, but risks include valuation sensitivity and competitive pressures. The stock offers upside to analyst targets but requires monitoring of execution and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
